中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 9
Sep.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(9): 2092-2096

Influencing factors of rebleeding after gastroscopy in patients with liver cirrhosis and esophagogastric variceal bleeding

DOI: 10.3969/j.issn.1001-5256.2021.09.018

  • Department of Hepatology, Tianjin Third Central Hospital; The Third Central Clinical College of Tianjin Medical University; Tianjin Institute of Hepatobiliary Disease, Tianjin 300170, China

Research funding:

National Science and Technology Major Project on Prevention and Treatment of Major Infectious Diseases Including AIDS and Viral Hepatitis (2017ZX10203202)

  • Received Date: 2021-01-20
  • Accepted Date: 2021-04-06
  • Published Date: 2021-09-20
    Abstract
  •   Objective  To investigate the influencing factors for rebleeding after gastroscopy in patients with liver cirrhosis and esophagogastric variceal bleeding.  Methods  A retrospective analysis was performed for the clinical data of the patients with liver cirrhosis and esophagogastric variceal bleeding who were hospitalized in Tianjin Third Central Hospital from January 1, 2017 to December 31, 2018, and according to the presence or absence of rebleeding and bleeding time, the patients were divided into non-bleeding group (n=148) and bleeding group (n=119). The risk factors for rebleeding after gastroscopy were analyzed. The t-test or the Mann-Whitney U test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups. The Cox regression model was used for univariate and multivariate analyses. The receiver operating characteristic (ROC) curve was used to evaluate the accuracy of Child-Turcotte-Pugh (CTP), fibrosis-4 (FIB-4), and albumin-bilirubin (ALBI) scores in predicting rebleeding after gastroscopy, and MedCalc was used to compare the area under the ROC curve (AUC).  Results  A total of 267 patients with liver cirrhosis and esophagogastric variceal bleeding were enrolled, among whom 53 (19.9%) had liver cancer. A total of 119 patients suffered from rebleeding, with an overall rebleeding rate of 44.6% and a median time to rebleeding of 11.0 (0-39.0) months. The univariate Cox regression analysis showed that liver cancer (hazard ratio [HR]=0.377, P < 0.001), aspartate aminotransferase (AST) (HR=1.002, P=0.025), serum Na (HR=0.935, P=0.004), and FIB-4 (HR=1.030, P=0.049) were associated with rebleeding, and the multivariate Cox regression analysis showed that liver cancer (HR=0.357, P < 0.001), AST (HR=1.003, P=0.030), prothrombin time (PT) (HR=0.196, P=0.001), CTP score (HR=1.289, P=0.014), FIB-4 (HR=1.062, P=0.033), and ALBI score (HR=0.433, P=0.011) were independent risk factors for rebleeding. CTP, FIB-4, and ALBI scores had an AUC of 0.711 (95% confidence interval [CI]: 0.647-0.776), 0.705 (95% CI: 0.640-0.770), and 0.730 (95% CI: 0.667-0.793), respectively, in predicting rebleeding. There was no significant difference in AUC between CTP, FIB-4, and ALBI scores (P > 0.05).  Conclusion  Liver cancer, AST, PT, CTP score, FIB-4 score, and ALBI score are associated with rebleeding after gastroscopy in patients with liver cirrhosis and esophagogastric variceal bleeding, among which CTP, FIB-4, and ALBI scores have a good value in predicting rebleeding outcome, while there is no significant difference in predictive ability between them.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association. Expert consensus on diagnosis and treatment of esophagogastric variceal bleeding in cirrhotic portal hypertension(2019 edition)[J]. Chin J Pract Surg, 2019, 39(12): 1241-1247. DOI: 10.19538/j.cjps.issn1005-2208.2019.12.01.

    中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版)[J]. 中国实用外科杂志, 2019, 39(12): 1241-1247. DOI: 10.19538/j.cjps.issn1005-2208.2019.12.01.
    [2]
    BOSCH J, GARCÍA-PAGÁN JC. Prevention of variceal rebleeding[J]. Lancet, 2003, 361(9361): 952-954. DOI: 10.1016/S0140-6736(03)12778-X.
    [3]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Endoscopy, Chinese Medical Association. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002.
    [4]
    REN LM, DANG T, MENG XM, et al. Analysis of risk factors for early rebleeding after endoscopic treatment of cirrhotic esophageal varices bleeding[J/C]. Chin J Gastrointestinal Endoscopy (Electronic Edition), 2019, 6(2): 57-61. DOI: 10.3877/cma.j.issn.2095-7157.2019.02.002.

    任丽梅, 党彤, 孟宪梅, 等. 肝硬化食管静脉曲张出血内镜治疗后早期再出血的危险因素分析[J/CD]. 中华胃肠内镜电子杂志, 2019, 6(2): 57-61. DOI: 10.3877/cma.j.issn.2095-7157.2019.02.002.
    [5]
    ALTAMIRANO J, ZAPATA L, AGUSTIN S, et al. Predicting 6-week mortality after acute variceal bleeding: Role of classification and regression tree analysis[J]. Ann Hepatol, 2009, 8(4): 308-315. http://journals.indexcopernicus.com/fulltxt.php?ICID=900181
    [6]
    KRIGE JE, SHAW JM, BORNMAN PC, et al. Early rebleeding and death at 6 weeks in alcoholic cirrhotic patients with acute variceal bleeding treated with emergency endoscopic injection sclerotherapy[J]. S Afr J Surg, 2009, 47(3): 72-74, 76-79.
    [7]
    ROUT G, SHARMA S, GUNJAN D, et al. Development and validation of a novel model for outcomes in patients with cirrhosis and acute variceal bleeding[J]. Dig Dis Sci, 2019, 64(8): 2327-2337. DOI: 10.1007/s10620-019-05557-y.
    [8]
    HWANG JH, SHERGILL AK, ACOSTA RD, et al. The role of endoscopy in the management of variceal hemorrhage[J]. Gastrointest Endosc, 2014, 80(2): 221-227. DOI: 10.1016/j.gie.2013.07.023.
    [9]
    LEUNG JC, LOONG TC, PANG J, et al. Invasive and non-invasive assessment of portal hypertension[J]. Hepatol Int, 2018, 12(Suppl 1): 44-55. DOI: 10.1007/s12072-017-9795-0.
    [10]
    ZHOU SY, DUAN ZH. Noninvasive diagnosis of esophageal varices in liver cirrhosis[J]. J Clin Hepatol, 2020, 36(8): 1842-1846. DOI: 10.3969/j.issn.1001-5256.2020.08.036.

    周胜云, 段志辉. 肝硬化食管静脉曲张的无创诊断[J]. 临床肝胆病杂志, 2020, 36(8): 1842-1846. DOI: 10.3969/j.issn.1001-5256.2020.08.036.
    [11]
    KRAJA B, MONE I, AKSHIJA I, et al. Predictors of esophageal varices and first variceal bleeding in liver cirrhosis patients[J]. World J Gastroenterol, 2017, 23(26): 4806-4814. DOI: 10.3748/wjg.v23.i26.4806.
    [12]
    HASSAN EM, OMRAN DA, EL BESHLAWEY ML, et al. Can transient elastography, Fib-4, Forns Index, and Lok Score predict esophageal varices in HCV-related cirrhotic patients?[J]. Gastroenterol Hepatol, 2014, 37(2): 58-65. DOI: 10.1016/j.gastrohep.2013.09.008.
    [13]
    KOTHARI HG, GUPTA SJ, GAIKWAD NR, et al. Role of non-invasive markers in prediction of esophageal varices and variceal bleeding in patients of alcoholic liver cirrhosis from central India[J]. Turk J Gastroenterol, 2019, 30(12): 1036-1043. DOI: 10.5152/tjg.2019.18334.
    [14]
    LIN PT, TENG W, JENG WJ, et al. The incidence and predictors of post transarterial chemoembolization variceal bleeding in hepatocellular carcinoma patients[J]. J Formos Med Assoc, 2020, 119(2): 635-643. DOI: 10.1016/j.jfma.2019.08.019.
    [15]
    CHAN AW, KUMADA T, TOYODA H, et al. Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2016, 31(7): 1300-1306. DOI: 10.1111/jgh.13291.
    [16]
    HSIEH YC, LEE KC, WANG YW, et al. Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI score[J]. PLoS One, 2018, 13(12): e0208903. DOI: 10.1371/journal.pone.0208903.
    [17]
    TOYODA H, LAI PB, O'BEIRNE J, et al. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: Application of the ALBI grade[J]. Br J Cancer, 2016, 114(7): 744-750. DOI: 10.1038/bjc.2016.33.
    [18]
    ZOU D, QI X, ZHU C, et al. Albumin-bilirubin score for predicting the in-hospital mortality of acute upper gastrointestinal bleeding in liver cirrhosis: A retrospective study[J]. Turk J Gastroenterol, 2016, 27(2): 180-186. DOI: 10.5152/tjg.2016.15502.
    [19]
    XAVIER SA, VILAS-BOAS R, BOAL CARVALHO P, et al. Assessment of prognostic performance of Albumin-Bilirubin, Child-Pugh, and Model for End-stage Liver Disease scores in patients with liver cirrhosis complicated with acute upper gastrointestinal bleeding[J]. Eur J Gastroenterol Hepatol, 2018, 30(6): 652-658. DOI: 10.1097/MEG.0000000000001087.
    [20]
    FOUAD TR, ABDELSAMEEA E, ABDEL-RAZEK W, et al. Upper gastrointestinal bleeding in Egyptian patients with cirrhosis: Post-therapeutic outcome and prognostic indicators[J]. J Gastroenterol Hepatol, 2019, 34(9): 1604-1610. DOI: 10.1111/jgh.14659.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (713) PDF downloads(43) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return